Thursday, June 25, 2026
🇺🇸 FDA

Clinical Tools · Cardiovascular Risk · Chest Pain

HEART Score Calculator

Calculate the HEART score (0–10) for emergency department chest pain from history, ECG, age, risk factors, and troponin. Built for MACE risk stratification, troponin ULN interpretation, and cardiovascular trial endpoint context.

Quick Answer

The HEART score (0–10) stratifies emergency department chest pain patients by major adverse cardiac event (MACE) risk using History, ECG, Age, Risk factors, and Troponin. Low scores (0–3) support early discharge pathways; scores 4–6 warrant observation; scores 7–10 suggest high short-term event risk. Pharma teams reference HEART for ACS trial endpoint literacy and troponin-based diagnostic algorithm context.

HEART score components
HEART = History + ECG + Age + Risk factors + Troponin
Each component 0–2 points · Total 0–10 · Low 0–3 · Moderate 4–6 · High 7–10 (MACE risk).

Calculate HEART Score

Select the clinical category for each HEART component. Use the troponin assay ULN from your laboratory when interpreting troponin elevation.

HEART components

Chest pain character, radiation, diaphoresis, and associated symptoms.

Hypertension, hypercholesterolemia, diabetes, obesity, smoking, family history of CAD, or prior CAD/PAD/CVD.

Use assay-specific ULN. High-sensitivity pathways may map results to these fold bands per local protocol.

MACE risk band

-

-

-

HEART score
-
points (0–10)
History
-
points
ECG
-
points
Age
-
points
Risk factors
-
points
Troponin
-
points

How to Use the HEART Calculator

1
Assess history, ECG, age, cardiovascular risk factors, and index troponin from the same ED presentation window.
2
Map troponin to multiples of the assay ULN (≤ ULN, 1–3× ULN, >3× ULN). Confirm ULN with your laboratory reference interval.
3
Sum component points (0–2 each) for a total HEART score from 0 to 10.
4
Interpret the MACE risk band (low 0–3, moderate 4–6, high 7–10) and align disposition with institutional chest pain pathways—not as a standalone diagnosis.

Worked Example

Example calculation

Presentation: 55-year-old with moderately suspicious chest pain, normal ECG, two cardiovascular risk factors (hypertension and diabetes), troponin 1.8× ULN on index draw.

Component scores: History 1 + ECG 0 + Age 1 + Risk factors 1 + Troponin 1 = 4 points.

Interpretation: HEART 4 falls in the moderate MACE risk band (4–6). Typical pathways include observation, serial troponin, and cardiology assessment per local protocol.

MACE Definition for Trial Context

In HEART validation cohorts, major adverse cardiovascular events (MACE) typically refers to a short-term composite—often within six weeks—of all-cause death, myocardial infarction, and need for coronary revascularization (PCI or CABG). This differs from many registrational cardiovascular drug trials, where primary MACE composites may additionally include stroke, hospitalization for heart failure, or other protocol-specific components over months to years.

When interpreting HEART for research operations, distinguish the ED rule-out MACE window from trial endpoint definitions. Document which MACE composite applies in protocol synopses, statistical analysis plans, and adjudication charters.

HEART Score Interpretation Bands

Low risk 0 – 3 points

Low short-term MACE risk (~1–2% in original validation cohorts). May support accelerated rule-out pathways where guideline-appropriate.

Moderate risk 4 – 6 points

Intermediate MACE risk. Observation, serial biomarkers, and additional non-invasive or invasive testing often warranted.

High risk 7 – 10 points

High MACE risk. Early cardiology involvement, admission, and expedited ACS evaluation typically indicated.

Cardiovascular Drug Trials — Risk Stratification Context

HEART is an acute ED chest pain stratification tool, not a chronic therapy enrollment score. For pharmaceutical and clinical operations teams, its relevance lies in aligning site training on acute cardiovascular presentations, documenting baseline acute risk in ED-enriched ACS trials, and distinguishing short-term presentation risk from long-horizon trial MACE endpoints.

Secondary prevention and antithrombotic trials typically stratify by established cardiovascular disease, diabetes, renal function, and biomarker profiles rather than HEART bands. For NNT and absolute risk reduction interpretation of trial results, use our NNT Calculator alongside protocol-specific event definitions.

Anticoagulation trials in atrial fibrillation use CHA2DS2-VASc and HAS-BLED for stroke versus bleeding risk—not HEART. See our CHA2DS2-VASc Score and HAS-BLED Score calculators for chronic anticoagulation risk context.

HEART vs TIMI and Troponin Cutoffs

HEART vs TIMI: TIMI scores apply to patients with suspected or confirmed ACS and emphasize ACS severity markers. HEART targets undifferentiated ED chest pain before ACS is established and integrates troponin fold elevation at presentation. Many low-risk HEART patients would not meet TIMI enrollment criteria because TIMI assumes ACS context.

Troponin cutoffs: Classic HEART troponin scoring uses ≤ ULN (0), 1–3× ULN (1), and >3× ULN (2). High-sensitivity troponin assays and 0/1-hour algorithms may use absolute ng/L thresholds; map those results to HEART categories per institutional pathway when using this score in quality or training documentation.

Limitations and Caveats

HEART performance varies by population, troponin assay generation, and serial sampling protocols. A single index troponin may underestimate evolving MI; serial measurement remains standard in moderate and high bands.

Do not apply HEART to clear STEMI, hemodynamic instability, or presentations where immediate reperfusion or invasive evaluation is indicated regardless of score. Risk factor counting depends on accurate history and problem list documentation.

HEART estimates short-term MACE risk at presentation; it does not predict long-term cardiovascular outcomes, guide anticoagulation, or replace QT interval assessment for drug safety. For QTc monitoring in cardiovascular pharmacology, see our QTc Calculator.

Interpretation Reference Table

HEART score MACE risk band Approximate MACE rate Typical disposition
0 – 3 Low ~1–2% (validation cohorts) Rule-out pathway, early discharge with follow-up when pathway-supported
4 – 6 Moderate Intermediate Observation, serial troponin, provocative testing or CTA per protocol
7 – 10 High High Admission, cardiology consultation, expedited ACS evaluation

Evidence & sources

Frequently Asked Questions

The HEART score is a validated clinical decision tool for patients presenting to the emergency department with acute chest pain. It combines History, ECG, Age, Risk factors, and Troponin (HEART) into a 0–10 point score that estimates short-term risk of major adverse cardiovascular events (MACE).
Each HEART component scores 0, 1, or 2 points: History (slightly suspicious 0, moderately 1, highly 2), ECG (normal 0, nonspecific repolarization 1, significant ST deviation 2), Age (<45 0, 45–64 1, ≥65 2), Risk factors (none 0, 1–2 factors 1, ≥3 or known atherosclerotic disease 2), and Troponin (normal 0, 1–3× ULN 1, >3× ULN 2). The total ranges from 0 to 10.
In HEART validation studies, MACE typically refers to a composite of major adverse cardiovascular events within approximately six weeks: all-cause death, myocardial infarction (MI), and need for coronary revascularization (PCI or CABG). Exact endpoint definitions vary by cohort and protocol; trial teams should align scoring interpretation with their study-specific MACE definition.
Standard interpretation: 0–3 points indicates low MACE risk (approximately 1–2% in original validation cohorts), 4–6 points indicates moderate risk, and 7–10 points indicates high MACE risk. These bands guide disposition and further testing intensity but do not replace clinical judgment or institutional pathways.
TIMI (Thrombolysis in Myocardial Infarction) risk scores were developed for patients with established acute coronary syndromes, often after MI is already suspected. HEART was designed for undifferentiated ED chest pain before ACS is confirmed. HEART emphasizes troponin dynamics and ED-specific history/ECG patterns; TIMI focuses on ACS severity and is less suited as a primary rule-out tool in low-suspicion presentations.
HEART troponin scoring uses multiples of the assay upper limit of normal (ULN): normal (≤ ULN) scores 0, 1–3× ULN scores 1, and >3× ULN scores 2. Use the same troponin assay and ULN reference interval as your laboratory and clinical pathway. High-sensitivity troponin pathways may apply different absolute cutoffs even when mapped to HEART categories.
ULN is the manufacturer- and laboratory-specific upper reference limit for the troponin assay in use (e.g., troponin I or T). Divide the patient troponin result by that ULN to obtain the fold elevation. Serial troponin measurement and delta changes are often incorporated in modern pathways but the classic HEART score uses the index troponin value at presentation mapped to these fold bands.
Avoid relying on HEART alone when chest pain is clearly non-cardiac, when ECG shows definite STEMI, in hemodynamic instability, sustained arrhythmia, known acute MI, or when troponin results are not yet available in a protocol that requires serial sampling. HEART was validated in ED chest pain cohorts; it is not a substitute for stress testing, CTA, or invasive evaluation when guideline-indicated.
Many ED protocols stratify patients with HEART 0–3 to accelerated rule-out pathways or outpatient follow-up, HEART 4–6 to observation and serial troponin or provocative testing, and HEART 7–10 to early cardiology consultation and admission. Local guidelines, shared decision-making, and shared regional networks may modify these thresholds.
Cardiovascular trials often define primary endpoints as MACE composites (CV death, MI, stroke, hospitalization for heart failure, or revascularization). HEART estimates short-term event risk at presentation—it is not a trial endpoint calculator. However, baseline cardiovascular risk stratification in ambulatory or secondary prevention trials may reference similar clinical variables (age, risk factors, biomarkers).
HEART is an acute ED chest pain tool and is generally not used for chronic cardiovascular drug trial enrollment. For acute coronary syndrome or antithrombotic trials enrolling ED populations, sponsors may document baseline HEART or analogous risk scores as covariates or for site training consistency. Selection criteria should follow protocol-specific inclusion/exclusion and regulatory precedent—not HEART bands alone.
No. HEART supports risk stratification and disposition decisions; it does not diagnose ACS, exclude unstable angina in all populations, or replace coronary CTA, stress imaging, or invasive angiography when clinically indicated. High or indeterminate scores warrant further evaluation per institutional standards and patient-specific factors.

Related Tools

QTc QTc Calculator CHA₂DS₂ CHA₂DS₂-VASc Score HAS HAS-BLED Score NNT NNT Calculator

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.